Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
SHOULDER INNOVATIONS, INC. (SI) reported insider transactions by Chief Operating Officer Matthew Fraser Ahearn. On August 17–18, 2026, he sold a total of 22,500 shares of Common Stock in open-market transactions under a Rule 10b5-1 trading plan, at weighted average prices around $20–$21 per share across specified ranges. On August 14, 2026, he also made a bona fide gift of 2,500 shares of Common Stock.
Morgan Stanley Smith Barney LLC Executive Financial Services is listed as broker for the planned sale of 22,500 common shares of the issuer’s stock, with an indicated aggregate market value of $466,425.00 and 20,818,957 shares outstanding as of an intended sale date of 08/17/2026 on the NYSE. The shares were originally acquired in connection with a Preferred Equity Financing dated 11/17/2017. In the last three months, 10b5-1 plan sales for Matthew Ahearn included 4,144 common shares for $78,069.64 on 06/15/2026 and 15,856 common shares for $296,185.32 on 06/12/2026.
SHOULDER INNOVATIONS, INC. reports that Chief Commercial Officer Jonathan E. Osborne beneficially owns 60,355 shares of Common Stock directly. He also holds stock options over 24,870 shares at an exercise price of $2.48 expiring on July 12, 2034, 19,423 shares at $2.86 expiring on April 23, 2035, and 126,357 shares at $14.16 expiring on January 30, 2033. Footnotes describe graded vesting schedules, including options that vested one-fourth initially with the remainder vesting in 12 equal quarterly increments, and another grant vesting one-fourth annually on March 1 starting in 2027.
Shoulder Innovations, Inc., a commercial-stage medical technology company focused on the shoulder surgical care market, has promoted Jon Osborne to Chief Commercial Officer, effective August 6, 2026. He previously served as Vice President of Commercial Development and will now oversee all elements of the company’s commercial organization.
Osborne will work closely with the Customer Experience and Medical Education team to execute the company’s commercial strategy, emphasizing scaling the organization, deepening surgeon and partner relationships, and aligning commercial execution with the company’s innovation efforts. The company highlights his extensive orthopedic industry background and prior leadership roles at Smith & Nephew and other medical device firms.
Gilde Healthcare and related Dutch entities report holding an aggregate of 2,212,207 shares of Shoulder Innovations, Inc. common stock, representing 10.7% of the company. This percentage is based on 20,738,226 shares outstanding as of May 6, 2026, as stated in a Form 10-K filed May 13, 2026.
Gilde Healthcare is the record holder, while affiliated management entities may be deemed to share voting and dispositive power over these shares. The group also discloses recent open-market sales between July 30 and August 6, 2026, including 99,812 shares sold on August 4 at a weighted average price of $22.77 per share, with other smaller sales priced roughly between $22.60 and $23.73.
Gilde Healthcare Holding B.V., a 10% owner of Shoulder Innovations, reported indirect open-market sales totaling 9,433 common shares. On August 5, 2026 an affiliated entity sold 7,338 shares at a $22.64 weighted-average price from $22.60–$23.00, followed by 2,095 shares at $22.60 on August 6, 2026. The shares are held of record by Cooperatieve Gilde Healthcare V U.A., over which Gilde-related entities have voting and dispositive power.
Shoulder Innovations, Inc. has filed a mixed shelf registration allowing it to offer, from time to time, up to $300,000,000 of securities, including common stock, preferred stock, debt securities, warrants, subscription rights and units, in one or more offerings after effectiveness, with specific terms to be set in prospectus supplements.
The filing also registers up to 8,103,026 shares of common stock for resale by existing selling stockholders; these holders will receive all proceeds from their sales, while the company will receive none. Shoulder Innovations’ common stock trades on the NYSE under “SI,” and 20,761,754 shares of common stock were outstanding as of June 30, 2026. The company is a commercial-stage medical technology business focused on shoulder arthroplasty implant systems and related enabling technologies.
Shoulder Innovations, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Net revenue reached $17,175 thousand, up 56.0% from a year earlier, driven by higher procedure volumes; implant systems sold increased to 2,238 from 1,503. Gross margin improved to 78.3%, reflecting scale benefits and pricing.
Operating loss widened to $10,036 thousand as selling, general and administrative expenses increased 56.3% and research and development 141.2%, supporting commercial expansion and a robotics platform partnership. However, net loss narrowed to $10,153 thousand from $19,196 thousand, mainly because prior-year results included an $11,719 thousand non-cash Series E purchase option fair value charge. Adjusted EBITDA loss improved to $8,023 thousand from $18,073 thousand.
For the first half of 2026, net revenue grew 60.2% to $33,883 thousand, with gross margin of 78.0%. The company ended June with $98,993 thousand in cash, cash equivalents and marketable securities and a new $15,000 thousand term loan plus a $30,000 thousand undrawn revolving credit facility with Stifel Bank.
Shoulder Innovations reported strong second quarter 2026 results, with net revenue of $17.2 million, a 56% increase over the prior-year quarter, and gross margin expanding to 78.3% from 76.2%. Growth was driven by higher implant volumes, more customers and a higher average selling price of $7,674.
The company sold 2,238 implant systems, about 50% more than a year earlier, but continued to invest heavily, lifting selling, general and administrative expenses to $20.1 million and research and development to $3.4 million. Operating loss widened to $10.0 million, while net loss narrowed to $10.2 million and Adjusted EBITDA loss to $8.0 million.
Shoulder Innovations closed two new credit facilities totaling up to $50 million and ended June 30, 2026 with $99.0 million in cash, cash equivalents and marketable securities. On this basis it raised full-year 2026 net revenue guidance to $67–69 million, implying about 42–46% growth over 2025.